ACAD ACADIA Pharmaceuticals Inc.

17.67
-0.26  -1%
Previous Close 17.93
Open 17.79
Price To Book 9.87
Market Cap 2210067422
Shares 125,074,557
Volume 1,152,440
Short Ratio
Av. Daily Volume 2,653,223

NewsSee all news

  1. Why ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Could Be Your Next Investment
  2. See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc.
  3. Analysis: Positioning to Benefit within Symantec, ACADIA Pharmaceuticals, Novavax, BBX Capital, Paychex, and US Foods Holding — Research Highlights Growth, Revenue, and Consolidated Results
  4. ACADIA Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
  5. Why Acadia Pharmaceuticals Stock Rose 20.8% Yesterday

SEC filingsSee all SEC filings

  1. SC 13D/A [Amend] - General statement of acquisition of beneficial ownership 181217615
  2. 8-K - Current report 181206460
  3. 424B5 - Prospectus [Rule 424(b)(5)] 181206443
  4. 424B5 - Prospectus [Rule 424(b)(5)] 181201185
  5. S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers 181200928

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data released October 31, 2018 - noted overall primary endpoint met BUT did not benefit placebo in re-randomized stage.
Pimavanserin - CLARITY
Adjunctive Treatment in Patients With Major Depressive Disorder
Phase 2 initiated November 2016. Enrolment to be completed 2H 2019.
Pimavanserin - Advance
Adjunctive treatment in patients with negative symptoms of schizophrenia
Phase 3 initiated November 2016. Data due mid-2019.
Pimavanserin - Enhance
Adjunctive treatment of schizophrenia
Announced October 4, 2017 that trial will be discontinued.
Pimavanserin - SERENE
Alzheimer’s disease agitation
Approved April 29 2016. Additional dose approval announced June 29, 2018.
Pimavanserin
Parkinson’s disease psychosis (PDP)
Phase 3 interim data 2H 2019.
Pimavanserin - Harmony
Alzheimer’s disease psychosis

Latest News

  1. Why ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Could Be Your Next Investment
  2. See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc.
  3. Analysis: Positioning to Benefit within Symantec, ACADIA Pharmaceuticals, Novavax, BBX Capital, Paychex, and US Foods Holding — Research Highlights Growth, Revenue, and Consolidated Results
  4. ACADIA Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
  5. Why Acadia Pharmaceuticals Stock Rose 20.8% Yesterday
  6. Here's Why Acadia Pharmaceuticals Is Soaring
  7. Today’s Research Reports on Stocks to Watch: Loxo Oncology and ACADIA Pharmaceuticals
  8. ACADIA Pharmaceuticals Prices Public Offering of Common Stock
  9. The Daily Biotech Pulse: Abeona Fires CEO, Loxo Passes FDA Muster, Bristol-Myers Flunks Lung Cancer Trial
  10. Today's Research Reports on Trending Tickers: Novavax and ACADIA Pharmaceuticals
  11. ACADIA Pharmaceuticals Announces Proposed Public Offering of Common Stock
  12. A Look at Amarin Corporation’s Stock Performance Year-to-Date
  13. Edited Transcript of ACAD earnings conference call or presentation 6-Nov-18 10:00pm GMT
  14. Analysts Expect Breakeven For ACADIA Pharmaceuticals Inc (NASDAQ:ACAD)
  15. Acadia Pharmaceuticals (ACAD) Reports Q3 Loss, Tops Revenue Estimates
  16. Acadia: 3Q Earnings Snapshot
  17. ACADIA Pharmaceuticals Reports Third Quarter 2018 Financial Results

SEC Filings

  1. SC 13D/A [Amend] - General statement of acquisition of beneficial ownership 181217615
  2. 8-K - Current report 181206460
  3. 424B5 - Prospectus [Rule 424(b)(5)] 181206443
  4. 424B5 - Prospectus [Rule 424(b)(5)] 181201185
  5. S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers 181200928
  6. 8-K - Current report 181195955
  7. 10-Q - Quarterly report [Sections 13 or 15(d)] 181163213
  8. 8-K - Current report 181163156
  9. 8-K - Current report 181158196
  10. 8-K - Current report 181148742